Insider Trading Alert - ENOC, QTS And KERX Traded By Insiders

Yesterday, Nov. 12, 2015, 171 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $70,050,500.00.

Highlighted Stocks Traded by Insiders:

EnerNOC (ENOC) - FREE Research Report

Brewster David B, who is President at EnerNOC, bought 25,000 shares at $4.11 on Nov. 12, 2015. Following this transaction, the President owned 1.2 million shares meaning that the stake was boosted by 2.11% with the 25,000-share transaction.

The shares most recently traded at $4.26, up $0.15, or 3.52% since the insider transaction. Historical insider transactions for EnerNOC go as follows:

  • 4-Week # shares bought: 20,597
  • 4-Week # shares sold: 21,342
  • 12-Week # shares bought: 20,597
  • 12-Week # shares sold: 21,342
  • 24-Week # shares bought: 20,597
  • 24-Week # shares sold: 21,342

The average volume for EnerNOC has been 350,000 shares per day over the past 30 days. EnerNOC has a market cap of $122.9 million and is part of the services sector and diversified services industry. Shares are down 71% year-to-date as of the close of trading on Thursday.

EnerNOC, Inc. provides energy intelligence software (EIS) and related solutions for commercial, institutional, and industrial customers. Currently, there are 3 analysts who rate EnerNOC a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENOC - FREE

TheStreet Quant Ratings rates EnerNOC as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, poor profit margins and weak operating cash flow. Get the full EnerNOC Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

QTS Realty (QTS) - FREE Research Report

GA QTS Interholdco, LLC, who is 10% Owner at QTS Realty, sold 1.7 million shares at $41.45 on Nov. 12, 2015. Following this transaction, the 10% Owner owned 4.2 million shares meaning that the stake was reduced by 28.5% with the 1.7 million-share transaction.

The shares most recently traded at $41.87, up $0.42, or 1% since the insider transaction. Historical insider transactions for QTS Realty go as follows:

  • 4-Week # shares sold: 3,041
  • 12-Week # shares sold: 264,041
  • 24-Week # shares sold: 2.6 million

The average volume for QTS Realty has been 309,800 shares per day over the past 30 days. QTS Realty has a market cap of $1.7 billion and is part of the financial sector and real estate industry. Shares are up 24.67% year-to-date as of the close of trading on Thursday.

QTS Realty Trust, Inc. focuses on the ownership, development, and operation of carrier-neutral data centers in the United States. The company was founded in 2013 and is headquartered in Overland Park, Kansas. The stock currently has a dividend yield of 3.04%. The company has a P/E ratio of 71.3. Currently, there are 5 analysts who rate QTS Realty a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on QTS - FREE

TheStreet Quant Ratings rates QTS Realty as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full QTS Realty Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Keryx Biopharmaceuticals (KERX) - FREE Research Report

Madison Greg, who is President and CEO at Keryx Biopharmaceuticals, sold 1,638 shares at $5.18 on Nov. 12, 2015. Following this transaction, the President and CEO owned 115,081 shares meaning that the stake was reduced by 1.4% with the 1,638-share transaction.

The shares most recently traded at $5.06, down $0.12, or 2.37% since the insider transaction. Historical insider transactions for Keryx Biopharmaceuticals go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 1,011
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 1,011
  • 24-Week # shares bought: 29,984
  • 24-Week # shares sold: 8,481

The average volume for Keryx Biopharmaceuticals has been 2.6 million shares per day over the past 30 days. Keryx Biopharmaceuticals has a market cap of $543.8 million and is part of the health care sector and drugs industry. Shares are down 65.44% year-to-date as of the close of trading on Thursday.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Currently, there are 5 analysts who rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KERX - FREE

TheStreet Quant Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full Keryx Biopharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.